We are live on
!
Find out more
Rockefeller Capital Management Portfolio holdings
AUM
$56.4B
1-Year Est. Return
24.96%
This Fund
S&P 500
This Quarter
Est. Return
-0.57%
1 Year Est. Return
+24.96%
3 Year Est. Return
+83.53%
5 Year Est. Return
+100.91%
10 Year Est. Return
–
AUM
$19B
AUM Growth
+$1.28B
(+7.2%)
Cap. Flow
+$1.55B
Cap. Flow
% of AUM
8.12%
Top 10 Holdings %
Top 10 Hldgs %
20.03%
Holding
3,992
New
448
Increased
1,821
Reduced
816
Closed
180
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Elanco Animal Health
ELAN
|
+$89.1M |
| 2 |
WEX
WEX
|
+$78.4M |
| 3 |
Blackrock
BLK
|
+$73.2M |
| 4 |
Vanguard S&P 500 ETF
VOO
|
+$71.9M |
| 5 |
OneMain Financial
OMF
|
+$45.3M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Regeneron Pharmaceuticals
REGN
|
+$63.6M |
| 2 |
Neurocrine Biosciences
NBIX
|
+$56.6M |
| 3 |
Agnico Eagle Mines
AEM
|
+$55.1M |
| 4 |
DFS
Discover Financial Services
DFS
|
+$36M |
| 5 |
ORBC
ORBCOMM, Inc.
ORBC
|
+$27.5M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 20.39% |
| 2 | Financials | 14.65% |
| 3 | Healthcare | 12.11% |
| 4 | Consumer Discretionary | 7.54% |
| 5 | Industrials | 6.86% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
926
Globus Medical
GMED
$11.2B
| $1.23M | 0.01% |
16,010
+516
| +3% | +$41.4K |
|
927
Robert Half
RHI
$4.37B
| $1.22M | 0.01% |
12,168
-4,383
| -26% | -$429K |
|
928
Bio-Rad Laboratories Class A
BIO
$9.42B
| $1.21M | 0.01% |
1,624
-106
| -6% | -$79.4K |
|
929
Vanguard Morningstar Mid-Cap Value ETF
VOE
$24B
| $1.21M | 0.01% |
8,669
+560
| +7% | +$79.5K |
|
930
Leggett & Platt
LEG
$1.31B
| $1.21M | 0.01% |
26,985
+26,388
| +4,420% | +$1.27M |
|
931
FT Vest US Equity Buffer ETF February
FFEB
$1.41B
| $1.21M | 0.01% |
32,931
+4,264
| +15% | +$158K |
|
932
Ingredion
INGR
$6.58B
| $1.2M | 0.01% |
13,532
-444
| -3% | -$39.1K |
|
933
Coinbase
COIN
$40.5B
| $1.2M | 0.01% |
5,278
-688
| -12% | -$169K |
|
934
Corteva
CTVA
$51.3B
| $1.19M | 0.01% |
28,407
-4,989
| -15% | -$216K |
|
|
PTRA
935
DELISTED
Proterra Inc. Common Stock
PTRA
| $1.19M | 0.01% |
117,700
+60,700
| +106% | +$686K |
|
|
PPLT
936
abrdn Physical Platinum Shares ETF
PPLT
$2.02B
| $1.19M | 0.01% |
131,610
+29,660
| +29% | +$283K |
|
937
Bunge Global
BG
$20.8B
| $1.19M | 0.01% |
14,578
-209
| -1% | -$16.1K |
|
938
Atmos Energy
ATO
$28.8B
| $1.18M | 0.01% |
13,378
+11,548
| +631% | +$1.12M |
|
939
J.M. Smucker
SJM
$12.8B
| $1.18M | 0.01% |
9,833
-2,048
| -17% | -$260K |
|
940
WisdomTree Global ex-U.S. Quality Growth Fund
DNL
$501M
| $1.18M | 0.01% |
29,124
+7,354
| +34% | +$312K |
|
941
Essential Utilities
WTRG
$11.4B
| $1.18M | 0.01% |
25,569
+10,857
| +74% | +$526K |
|
942
iShares Core 1-5 Year USD Bond ETF
ISTB
$5.13B
| $1.18M | 0.01% |
+23,044
| New | +$1.18M |
|
943
Pacer Trendpilot US Large Cap ETF
PTLC
$3.38B
| $1.18M | 0.01% |
31,189
-3,896
| -11% | -$151K |
|
944
Molina Healthcare
MOH
$10.3B
| $1.17M | 0.01% |
4,308
+149
| +4% | +$39.4K |
|
945
Cognizant
CTSH
$26B
| $1.16M | 0.01% |
15,647
+2,359
| +18% | +$174K |
|
946
Invesco FTSE RAFI Emerging Markets ETF
PXH
$1.96B
| $1.16M | 0.01% |
51,794
+3,365
| +7% | +$76.5K |
|
|
UCTT
947
Ultra Clean Holdings
UCTT
$3.95B
| $1.15M | 0.01% |
27,086
+26,782
| +8,810% | +$1.26M |
|
|
MDLA
948
DELISTED
Medallia, Inc.
MDLA
| $1.15M | 0.01% |
34,064
+30,130
| +766% | +$1.01M |
|
949
Invesco Emerging Markets Sovereign Debt ETF
PCY
$1.4B
| $1.15M | 0.01% |
43,199
+9,209
| +27% | +$253K |
|
950
NovoCure
NVCR
$1.91B
| $1.15M | 0.01% |
9,875
+8,624
| +689% | +$1.3M |
|
Similar funds
NAMI
Rockefeller Capital Management's Q3 2021 Portfolio in Review
As of Q3 2021, Rockefeller Capital Management held 3,992 positions worth $19B, up 7.2% from $17.8B the previous quarter. Its ten largest holdings account for 20% of the portfolio.
Rockefeller Capital Management deployed $1.55B of net new capital in Q3 2021, opening 448 new positions and adding to 1,821 existing holdings. Its largest new stake was Darling Ingredients: 56,725 shares worth $4.08M.
By sector, the portfolio is most concentrated in Technology at 20% of assets, up from 20% a quarter earlier, followed by Financials and Healthcare.
On the sell side, the largest reduction was Regeneron Pharmaceuticals, an estimated $63.6M trimmed.
- Rockefeller Capital Management's largest Q3 2021 buy was Darling Ingredients: 56,725 shares worth $4.08M.
- Rockefeller Capital Management added most to Elanco Animal Health in Q3 2021, an estimated $89.1M increase.
- Rockefeller Capital Management's biggest Q3 2021 reduction was Regeneron Pharmaceuticals, cutting an estimated $63.6M.
- Rockefeller Capital Management fully exited ORBCOMM, Inc. in Q3 2021, selling an estimated $27.5M.
- Rockefeller Capital Management's ten largest holdings make up 20% of its $19B portfolio in Q3 2021.
- Rockefeller Capital Management opened 448 new positions and closed 180 in Q3 2021.
- Rockefeller Capital Management's portfolio value rose 7.2% quarter-over-quarter to $19B.
Based on Rockefeller Capital Management's 13F filing for Q3 2021, filed 12 Nov 2021.